-
Study aim
-
Evaluation of the effect of Colchicine therapy in patients presenting with non ST-elevation myocardial infarction
-
Design
-
Randomized, superiority, parallel group with double blind clinical trial. Simple randomization was performed using sealed envelope.
Sample size calculated according to high sensitive CRP as the main outcome and error of the first kind=5% and second type=10% and Comparison of two means formula, per group 70 patients.
-
Settings and conduct
-
The study will performed in 2019-2020 in Ghaem & Imam Reza hospitals in mashhad.
Patients in intervention and control groups respectively take Colchicine (0.5mg tiwce daily if weight more than 75 Kg & 0.5mg daily if weight less than 75 Kg or GFR less than 50) and placebo. For patients, evaluators and analysts will be blinded.
Initial laberatory tests Include CBC diff, hsCRP, ESR, Total cholesterol, HDL & LDL cholesterol, TG, Cr, CPK, ALP, AST, ALT, hsTroponin at hospitalize time and after 4 weeks will checked. By comparing data, results of the study will achieve.
-
Participants/Inclusion and exclusion criteria
-
Condition of entrace: Patients presenting with non STEMI
Non-entry condition: Renal failure & hemodialysis, GFR<30, thrombocytopenia, Sever hepatic failure, Dyspepsia, Chronic diarrhea, Under treatment by corticosteroids or immunosuppressive medications or Diltiazem or verapamil
-
Intervention groups
-
In intervention group and control group, patients will be treated by Colchicine and placebo
-
Main outcome variables
-
high sensitive CRP